Infection- and bleed-related mortality according to study and time
| Time (wk) . | Immunosuppression (GTH-AH 01/2010), N = 101∗ . | Emicizumab (GTH-AHA-EMI), N = 47∗ . | ||
|---|---|---|---|---|
| Fatal infections . | Fatal bleeds . | Fatal infections . | Fatal bleeds . | |
| 1-12 | 11 | 3 | – | 1 |
| 13-24 | – | – | 1 | 1 |
| 25-36 | 3 | – | 1 | – |
| 37-48 | – | – | – | – |
| 49-60 | – | – | – | – |
| 61-72 | 1 | – | – | – |
| 73-84 | – | – | – | – |
| 85-96 | 1 | – | – | – |
| Total | 16 (16) | 3 (3) | 2 (4) | 2 (4) |
| Time (wk) . | Immunosuppression (GTH-AH 01/2010), N = 101∗ . | Emicizumab (GTH-AHA-EMI), N = 47∗ . | ||
|---|---|---|---|---|
| Fatal infections . | Fatal bleeds . | Fatal infections . | Fatal bleeds . | |
| 1-12 | 11 | 3 | – | 1 |
| 13-24 | – | – | 1 | 1 |
| 25-36 | 3 | – | 1 | – |
| 37-48 | – | – | – | – |
| 49-60 | – | – | – | – |
| 61-72 | 1 | – | – | – |
| 73-84 | – | – | – | – |
| 85-96 | 1 | – | – | – |
| Total | 16 (16) | 3 (3) | 2 (4) | 2 (4) |
n (%).